CSL Limited
Australian biotech turning donated blood plasma into therapies, plus Seqirus flu vaccines.
On the record
Checkpoint: FY2026 full-year results, which will show if core plasma cash flow is stabilizing or if a third guidance cut follows
The call
CSL still holds a top spot in plasma therapies behind regulatory and network barriers, but a leadership change, impairments, and a stalled Seqirus spinoff mean 2026 is about proving the restructuring works, not fending off a new predator.
CSL is a major pharmaceutical company that collects blood plasma from donors and turns it into medicines for rare diseases and bleeding disorders. The business is hard to disrupt because it needs FDA and European approval, a huge network of blood donors, specialized factories, and long-term customer contracts, so rivals cannot easily copy it. However, the company cut its profit forecast twice in 2026, wrote down about US$5 billion in value, fired 15% of staff, its CEO suddenly retired, and postponed selling off its flu vaccine unit, which raises questions about whether management can execute the turnaround or whether deeper problems exist. The one thing to watch is the full-year results in August 2026 and who they hire as permanent CEO, because those two signals will show whether the core business is actually recovering or if the writedowns mask real operational trouble.
Why
01
AI pressure: None apparent. AI speeds up drug discovery industry-wide but does not replace plasma collection, fractionation plants, or donor networks CSL runs. Could AI do the core job? Unlikely.
02
Bigger players: Grifols and Takeda. Both already sell competing plasma therapies worldwide; no confirmed evidence yet they are pulling customers from CSL during its restructuring. Could a giant copy it? No, they are blocked.
03
What protects it. FDA/EMA-licensed fractionation plants, a huge owned plasma-donor network, and long-term hospital contracts that new entrants cannot quickly replicate.
What would change this call
CSL's FY2026 full-year results released around August 2026. Shows whether guidance holds or a third cut confirms deteriorating core cash flow.
CSL announces a permanent CEO appointment. Indicates whether strategy is operational stabilization or a break-up-and-sell mandate.
CSL Seqirus demerger is scheduled or further delayed beyond 2026. Signals whether restructuring plans are on track or stalling.
CSL announces a permanent CEO appointment. Indicates whether strategy is operational stabilization or a break-up-and-sell mandate.
CSL Seqirus demerger is scheduled or further delayed beyond 2026. Signals whether restructuring plans are on track or stalling.
Key numbers
- FY2025 revenue US$15.56bn, up 5% at constant currency
- 15% of global workforce and 22 US plasma centres cut
- May 2026 guidance cut to ~US$15.2bn revenue, ~US$3.1bn NPATA
Named risks
- Further guidance cuts or impairments beyond the ~US$5bn flagged in May 2026.
- Seqirus demerger further delayed or cancelled after October 2025 postponement.
- Permanent CEO appointment could signal break-up rather than operational focus.
- Execution risk from ongoing 15% workforce cut and plasma centre closures.
- US policy shifts on tariffs or Medicare Part D reform not assumed in guidance.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Grifols | contesting | Analysts flagged possible share gains during CSL restructuring disruption, May 2026 |
| Takeda | contesting | Named among peers positioned to exploit CSL's 2026 restructuring turmoil |
| Octapharma | contesting | Cited alongside Grifols/Takeda as potential beneficiary of CSL disruption, 2026 |
| Sanofi Pasteur | contesting | Primary flu-vaccine competitor to CSL Seqirus amid its delayed 2026 spinoff |
Questions people ask
- Is CSL Limited profitable in 2026?
- Yes but under pressure. H1 FY2026 reported NPAT collapsed 81% to US$401m due to about US$1.1bn in non-cash impairments (10 Feb 2026), and CSL cut full-year guidance on 11 May 2026 to roughly US$3.1bn NPATA with a further ~US$5bn in impairments flagged across FY26-FY27.
- Is CSL Limited laying off workers?
- Yes. On 20 August 2025 CSL announced plans to cut up to 15% of its global workforce, roughly 3,000 to 4,350 roles, alongside closing 22 US plasma collection centres, about 7% of CSL Plasma's US footprint, as part of a broader restructuring.
- Could AI replace CSL Limited's business?
- No. CSL's core relies on a physical donor plasma network and FDA/EMA licensed manufacturing that AI cannot replicate. As of 2026 CSL uses AWS Deviation AI for trial-analytics and Salesforce Agentforce for donor engagement, but these augment operations rather than replace regulated collection and manufacturing.
- Who is CSL Limited's biggest competitor?
- Grifols, Takeda, Octapharma and Kedrion, together with CSL these five firms hold roughly 80% of the global plasma fractionation market per a July 2025 GM Insights report. Analysts in May 2026 flagged risk that these rivals could exploit CSL's ongoing restructuring disruption, though no confirmed share loss has been reported.
- Who owns CSL Limited?
- CSL is publicly traded on the ASX (ASX:CSL) with no controlling parent. As of 30 June 2025 its largest disclosed shareholders were BlackRock, Vanguard and State Street, each holding roughly 5-7% blocks, with market cap around A$56.5bn as of 23 July 2026.
- Will CSL Limited spin off Seqirus?
- Uncertain timing. CSL announced plans in August 2025 to demerge Seqirus as a standalone ASX-listed vaccine company by end of FY2026, but delayed the plan on 27 October 2025 citing volatile US flu-vaccine market conditions, and as of July 2026 no new target date has been confirmed.
Timeline
- 2026-05-11CSL cut FY26 guidance to ~US$15.2bn revenue, ~US$3.1bn NPATA, flagged ~US$5bn further impairments
- 2026-03-08Announced US$1.5bn expansion of Kankakee, Illinois plasma manufacturing site
- 2026-02-10CEO Paul McKenzie retired abruptly, Gordon Naylor named interim CEO
- 2025-12-04Opened A$1bn cell-based vaccine and antivenom plant in Melbourne
- 2025-10-27Seqirus demerger delayed beyond FY2026 citing US flu-vaccine market volatility
- 2025-08-20Announced up to 15% global workforce cut and closure of 22 US plasma centres
- 2025-08-17Resumed A$750m share buyback and announced R&D consolidation to 6 sites
- 1994-06-03Fully privatised via ASX listing
Revision history
24 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- CSL 2025 Annual Report, Page 140 (2025-07-30)
- CSL Limited (2026-07-17)
- gurufocus.com (2026-07-23)
- CSL 2025 Annual Report, Page 92 (2025-06-29)
- CSL 2025 Annual Report, Page 10 (2025-06-29)
- Investing.com (2026-02-10)
- ASX Announcement
- CSL 2025 Annual Report (2025-10-27)
- GM Insights (2025-07-31)
- BioSpace (2025-08-20)
- CSL Newsroom (2026-03-08)
- ts2.tech (2025-12-04)